This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 3

  • Nasal Glucagon
    Nasal glucagon is a biologic entity being studied for the treatment of severe hypoglycemia in people with diabetes treated with insulin.

    For more information on nasal glucagon clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-10/17/2017)

     

     
  • Ultra Rapid Insulin
    LY900014 (LY) is a novel formulation containing locally-acting excipients to accelerate insulin lispro absorption. LY900014 is a biologic entity being studied for the treatment of type 1 and type 2 diabetes

    For more information on LY900014 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-10/17/2017)

    None during this time period.

     
  • Empagliflozin
    BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic heart failure with either preserved or reduced ejection fraction.

    For more information on BI10773 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010 - 10/17/2017)

     
  • Empagliflozin
    BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for type 1 diabetes.

    For more information on BI10773 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-10/17/2017)

    None during this time period.

     

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 2

  • Dual Amylin Calcitonin Receptor Agonist
    DACRA-042 is a new biologic entity that acts as a dual agonist of both the amylin receptor and calcitonin receptor and is being studied for the treatment of diabetes.

    For more information on DACRA-042 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • GIP/GLP-1 Co-Agonist Peptide
    LY3298176 (GIP/GLP-1 Co-agonist Peptide) is a new biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of diabetes.

    For more information on LY3298176 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Dulaglutide Investigational Doses
    LY2189265 (dulaglutide), a glucagon-like peptide-1 analog, is a biologic entity being studied at investigational doses as a once-weekly treatment for type 2 diabetes.

    For more information on LY2189265 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 1

Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of October 17, 2017. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • Select NME
  • Select NILEX
  • Diagnostic
GTM-PQNKVL